Past ocular history. DME Case 1. Patient presents blurred VA. Hemoglobin A1c 11.5% -- patient states sugars have not been in good control

Similar documents
Diabetic Retinopatathy

Diagnosis and treatment of diabetic retinopathy. Blake Cooper MD Ophthalmologist Vitreoretinal Surgeon Retina Associates Kansas City

Diabetic Retinopathy: Managing the Extremes. J. Michael Jumper, MD West Coast Retina

The Diabetic Retinopathy Clinical Research Network. Management of DME in Eyes with PDR

Clinically Significant Macular Edema (CSME)

1/25/2018. Case Management Strategies in Diabetic Retinopathy. Case Study #1: Severe DME. DDOS: 3/31/2016 Va 20/400. Disclosures

Scott M. Pfahler D.O. Dayton Vitreo-Retinal Associates AOCOO-HNS Palm Springs, CA 2012

Jay M. Haynie, O.D.; F.A.A.O. Olympia Tacoma Renton Kennewick Washington

New Developments in the treatment of Diabetic Retinopathy

CENTENE PHARMACY AND THERAPEUTICS NEW DRUG REVIEW 2Q17 April May

Optical Coherence Tomography: Pearls for the Anterior Segment Surgeon Basic Science Michael Stewart, M.D.

Venous Occlusive Diseases

Retinal Vein Occlusion

Diabetic Macular Edema Treatment in the 21st Century

CSME BCVA. OCT Bevacizumab CMT CMT BCVA. BCVA LogMAR. p CMT NPDR PDR PDR. Bevacizumab PDR FDA. Ranibizumab. Bevacizumab.

THE ROLE OF anti-vegf IN DIABETIC RETINOPATHY AND AGE RELATED MACULAR DEGENERATION

Diabetic Retinopathy: Recent Advances in Treatment and Treatment Approaches

Retina Grandrounds. Retinal Grand Rounds Exhibition of Common Entities

Diabetic eye disease. Diabetic retinopathy. Sam S. Dahr, M.D. Retina Center of Oklahoma.

Recalcitrant Diabetic Macular Oedema: Therapeutic Options

The Human Eye. Cornea Iris. Pupil. Lens. Retina

Diabetic Retinopathy

Diabetic Retinopathy A Presentation for the Public

ADULT-ONSET FOVEOMACULAR VITELLIFORM DYSTROPHY. By: Chris Munnerlyn, OMT Student University of Arkansas for Medical Sciences

Mean Change in Visual Acuity Over 2 Years Baseline Visual Acuity 20/50 or Worse

Persistent Macular Thickening After Ranibizumab Treatment for Diabetic Macular Edema With Vision Impairment

Diabetic Retinopathy Update 2017

Eyes on Diabetics: How to Avoid Blindness in Diabetic Patient

Marcus Gonzales, OD, FAAO Cedar Springs Eye Clinic

Paradigm Shift in the treatment of Diabetic Retinopathy. Haytham I. S. Salti, MD Associate Professor

When to Refer to RETINA. Joseph M. Coney, MD February 17, 2017 Memphis, TN

Retina Conference. Janelle Fassbender, MD, PhD University of Louisville Department of Ophthalmology and Visual Sciences 09/04/2014

FROM OUTDATED TO UPDATED Eminence-Based Medicine


Facts About Diabetic Eye Disease

FA Conference. Lara Rosenwasser Newman, M.D. 10/2/14 University of Louisville Department of Ophthalmology and Visual Sciences

Diabetic Retinopathy

Front Line Diabetic Retinopathy What Not to Miss and Why

Clinical results of OPT-302 (VEGF-C/D Trap ) Combination Treatment in namd and DME

Brampton Hurontario Street Brampton, ON L6Y 0P6

Serious Eye diseases, New treatments. Mr. M. Usman Saeed MBBS, FRCS, FRCOphth Consultant Ophthalmologist

Clinical results of OPT-302 (VEGF-C/D Trap ) Combination Treatment in namd and DME

Billing Requirements for Intravitreal Injections. Financial Interest. Indications. Documentation. Documentation. Documentation

Navilas Clinical Results: Diabetic Macular Edema Introducing a Better Treatment Paradigm for Patients and Physicians

Diabetic Retinopathy Clinical Research Network

Preventing Avoidable Vision loss from Diabetic Retinopathy in Indian Country

Retinal Vein Occlusion (RVO) Treatment pathway- Northeast England. Retinal Vein Occlusion (RVO) with Macular oedema (MO)

RETINA. OCT in the Optometric Prac4ce OCT. New stuff 11/7/17 AMD. Disclosure Statement

Treatment for Central-Involved Diabetic Macular Edema in Eyes with Very Good Visual Acuity

Macular edema (ME) is the most common

Navigated Laser Therapy. A New Era in Retinal Disease Management

Diabetic Retinopathy Clinical Research Network

Diabetic Retinopathy Clinical Research Network

Diabetic Retinopathy Clinical Research Network

Retinal Complications of Obstructive Sleep Apnea A Growing Concern!

Diabetic maculopathy 11/ An update on. Miss Vasuki Sivagnanavel

8/8/17. Objectives. Proliferative Diabetic Retinopathy (PDR) Examining the Diabetic Patient: What Matters Most

We know diabetes is a common and growing problem as well as the leading cause

An Update on Branch Retinal Vein Occlusion Treatment Studies. Amiee Ho, O.D. Pacific University College of Optometry

Case Report Inherent Challenges in Managing Long Standing Refractory Diabetic Macular Edema

From Outdated to Updated: A Review of Important Clinical Trials in Ocular Disease from 2014

Goals/Objectives. Disclosures. Risk Factors RAO and RVO. Risk Factors. Retinal Artery Occlusions Branch and Central

A Patient s Guide to Diabetic Retinopathy

Correspondence should be addressed to Dmitrii S. Maltsev;

The Era of anti- - - VEGF Kirk L. Halvorson, OD

You can C-ME after Uveitis

OCT Angiography The Next Frontier

Cataract and Diabetic macular edema: What should I do?

Clinical Case Presentation. Branch Retinal Vein Occlusion. Sarita M. Registered Nurse Whangarei Base Hospital

Protocol. This trial protocol has been provided by the authors to give readers additional information about their work.

PART 1: GENERAL RETINAL ANATOMY

Interesting, unusual and eclectic cases from 2017 Robert A. Mittra, MD VitreoRetinal Surgery, P.A. Minneapolis, MN

04/11/2014. Retina Coding and Reimbursement 101. Financial Disclosure. Chief Complaint

Interesting, unusual, eclectic cases from 2017 Robert A. Mittra, MD VitreoRetinal Surgery, P.A. Minneapolis, MN

How Strongly Do You Feel That This Patient Has Glaucoma? % % % % %

ZEISS AngioPlex OCT Angiography. Clinical Case Reports

Clinical Trials in Diabetic Retinopathy. Harry W. Flynn Jr., M.D. Nidhi Relhan Batra, M.D.

My Favourite Cases Anthony B. Litwak, OD, FAAO VA Medical Center Baltimore, MD

Diabetic Retinopathy. Barry Emara MD FRCS(C) Giovanni Caboto Club October 3, 2012

Efficacy of intravitreal bevacizumab (Avastin TM ) for shortterm treatment of diabetic macular edema

DME DIAGNOSIS AND MANAGEMENT

DIABETIC RETINOPATHY (DR) PREFERRED PRACTICE PATTERNS (PPP) Philippines 2016

Disclosures. How small?

Neuropathy (NAION) and Avastin. Clinical Assembly of the AOCOO-HNS Foundation May 9, 2013

*Pleasesee amendment forpennsylvaniamedicaid at the endofthis CPB.

Diabetic retinopathy (DR) progressively

Vascular Disease Ocular Manifestations of Systemic Hypertension

Diabetic Retinopathy WHAT IS DIABETIC RETINOPATHY? WHAT CAUSES DIABETIC RETINOPATHY? WHAT ARE THE STAGES OF DIABETIC RETINOPATHY?

Molecular Biology of Diabetic Retinopathy

Current Insight Into Retinal Disease Management: Focus on DME and Intravitreal Corticosteroids

04/06/2015. Documentation Do s and Don ts In The Retina Practice. Financial Disclosure. Documentation Dos and Don ts

CURRENT TRENDS IN DIABETIC MACULAR EDEMA TREATMENT. Muge R. Kesen, MD

Is OCT-A Needed As An Investigative Tool During The Management Of Diabetic Macular Edema

Anti-VEGF drugs & CATT Results. in AMD. Apollo Hospitals, Hyderabad. Mallika Goyal, MD

EyePACS Grading System (Part 3): Detecting Proliferative (Neovascular) Diabetic Retinopathy. George Bresnick MD MPA Jorge Cuadros OD PhD

International Journal of Health Sciences and Research ISSN:

Diabetic retinopathy (DR) is the leading PROCEEDINGS EVIDENCE-BASED DATA IN THE TREATMENT OF DIABETIC RETINOPATHY*

EyeGene Inc. Contact Information Korea Health Industry Development Institute

Transcription:

Past ocular history Patient presents blurred VA DME Case 1 Hemoglobin A1c 11.5% -- patient states sugars have not been in good control PDR with macular edema OU Rishi Singh MD Cleveland Clinic OD OS 1

First treatment: Avastin OU PRP OU BASELINE BASELINE VA OD 20/30 VA OS 20/30 Options? 1. Focal Laser 2. Panretinal Laser 3. Anti-VEGF 4. Steroid VA OD 20/30 VA OS 20/30 1 MONTH Patient receives Avastin OU: Patient received PRP OD 1-week prior: Patient receives PRP OS at this visit: VA OD 20/70-2 VA OS 20/30 +3 Response to Avastin & PRP OD 1-week post PRP: 2 nd Avastin injection OD 6 MONTHS FROM BASELINE VISIT VA OD 20/70-2 VA OS 20/25-2 2

7 months since baseline visit OD: 1 month post 2 nd Avastin injection better by OCT: VA OD 20/25-2/+1 7 months since baseline visit OS: VA OD 20/20-1 Past ocular history NPDR with clinically significant macular edema DME Case Has received Avastin (8/10) (1x) switched to monthly Lucentis 0.3 mg since 12/10 (33x) Focal treatment 1x (5/13) OCT still demonstrated continued CME despite multiple injections and focal treatment in right eye 3

Transparency: 0 % Overlay: ILM-RPE Difference Transparency: 100 % Response to Lucentis injections Response to focal treatment 15 th injection VA 20/60 +2 Prior to focal VA 20/50-2 16 th injection VA 20/60 +1 1 month post-focal VA 20/50-2 17 th injection VA 20/60-2 Response to Lucentis injections post-focal treatment 30 th injection VA 20/60 Options? Switch to another anti-vegf? Steroid? Vitrectomy? 31 st injection VA 20/60 +1 PRP? 32 nd injection VA 20/50-1/+1 4

Decided on intravitreal TA (Triescence) Most recent visit Had mild steroid response 2 nd month post-injection IOP 27 Prior to injection VA 20/50-2 IOP 19 OCT mildly worse VA 20/50-2 1 month VA 20/50 +2 IOP 21 Past ocular history OS s/p PPV with improved acuity to 20/50 => ischemia eroded vision to 20/400 PDR TRD Case PRP OD 2x 5

Right Eye Right Eye Pre-PRP VA OD 20/30-2 1 month post-prp VA OD 20/30-2 VA OD 20/40 Options: 1. Anti-VEGF 2. Steroids 3. Observation 4. Surgery s/p Avastin OD Pre-op VA OD 20/40 1 month post-injection: VA OD 20/30 VA OD 20/40 6

3 weeks post-op 2 months post-op OCT and vision improving VA OD 20/500 OCT and vision still improving VA OD 20/500 Fovea: 243 69 Fovea: Not found Fovea: Not found Fovea: Not found Past ocular history NPDR with clinically significant macular edema OS Hx of focal laser OS DME Case 7

Pre-Navilas treatment Options: FA shows mild ischemic changes within the fovea no evidence of neovascularization elsewhere VA OS 20/40 1. Anti-VEGF 2. Steroid 3. Focal Laser 4. Combination treatment Pre-Navilas treatment Response to Navilas Baseline VA OS 20/40 Navilas treatment & treatment plan: OD OS 1 month VA OS 20/50 +1 21 May 2013 OS 21 May 2013 OS OS Focal Date:21 May 2013 9:39:08 AM Delivered spots: 147 Power: 100-100 mw; average: 100 mw Pulse duration: 100-100 ms; average: 100 ms Spot size: 100-100 µm; average: 100 µm Total applied power: 1.47 J 2 months VA OS 20/40 21 May 2013 OS 8

Response to Navilas Case 2: DME Month 2 to Month 3 3 months VA OS 20/40-2 42-year-old white man with newly diagnosed type 2 diabetes mellitus HgbA1C 11.2% Poor vision OU 6 months VA OS 20/40-1/+2 Month 3 to Month 6 20/200 OU Approach? 1. Address macular edema first OD 2. Address macular edema first OS 3. Bilateral anti-vegf injections 4. Bilateral steroid injections 5. PRP for severe NPDR 9

2 years Later s/p Best Regimen for this Patient? OD: Ranibizumab x 8; focal laser; bevacizumab x 4; now on exclusively bevacizumab for cost reasons Average 6 injections / year OS: Ranibizumab x 2; focal laser; bevacizumab x 2 Reluctant to treat further given poor vision A) Alternate anti-vegf each eye every 2 months for the foreseeable future B) Switch to steroid agent C) Add PRP to address VEGF drive / ischemia D) Observation only 20/20 20/80 Widefield Angiography 20/20 20/80 Best Regimen for this Patient? A) Alternate anti-vegf each eye every 2 months for the foreseeable future B) Switch to steroid agent C) Add PRP to address VEGF drive / ischemia D) Observation only 10

Case 3: DME 20/30 20/20 64-year-old demanding Beverly Hills matron with type 2 diabetes mellitus x 10 years last HgbA1C 7.4% presents for screening exam Happy with vision no complaints 20/30 20/20 Management Plan? Pt Declined Any Treatment 1 Year Later A) Observe OU B) Focal laser OU 20/30 20/20 C) Anti-VEGF OU D) Triamcinolone OU E) Anti-VEGF OD Observe OS 11

Now What? Vision Stable Still Asymptomatic A) Bevacizumab OD B) Ranibizumab OD C) Triamcinolone OD D) Continue observation OD Baseline Ranibizumab 0.3 mg OD #1 4 weeks later Observe (pt defers injection) 6 weeks later Ranibizumab 0.3 mg OD #2 20/30 20/30 20/30 4 weeks later Observe (pt defers injection) 20/30 8 weeks later Pt still deferring injections Asks for glasses to help OD 20/30 Next Steps for OD? Next Steps for OS? Still 20/20 1. A) Continue ranibizumab 2. B) Switch to bevacizumab 3. C) Switch to triamcinolone 4. Focal laser 5. Observe 1. A) Begin ranibizumab 2. B) Begin bevacizumab 3. C) Begin triamcinolone 4. Focal laser 5. Observe 12